Administration of ondansetron is associated with lethal outcome.
We report here the case of a child with a known muscular abnormality and susceptibility to malignant hyperthermia who abruptly died after receiving a therapeutic dose of ondansetron. Also, we discuss the pharmacodynamic relationship of ondansetron to malignant hyperthermia in a susceptible host.
Gener
Blanca
B
Clinical Genetics, Department of Pediatrics, Hospital de Cruces, Barakaldo, Spain.
Burns
Jarrett M
JM
Griffin
Susanne
S
Boyer
Edward W
EW
D000932:Antiemetics / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D002675:Child, Preschool; D004200:Diseases in Twins / Q000235:genetics; D017809:Fatal Outcome; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008305:Malignant Hyperthermia / Q000209:etiology* / Q000235:genetics; D020914:Myopathies, Structural, Congenital / Q000235:genetics*; D017294:Ondansetron / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D019837:Ryanodine Receptor Calcium Release Channel / Q000235:genetics*; D014310:Triplets; D014430:Twins, Monozygotic; D014839:Vomiting / Q000188:drug therapy
D000932:Antiemetics; D019837:Ryanodine Receptor Calcium Release Channel; D017294:Ondansetron